

# UNIVERSITY OF TORONTO

## Microbiology & Infectious Diseases Research Days

Monday, June 3rd, 2019 – Trainee Day (Selected from Abstracts)

Tuesday, June 4th, 2019 – Invited Lectures & Poster Session

---

**Talks in Medical Sciences Building, Room 2170**

**Posters & Lunch in Medical Sciences Building,  
Room 2171 (C. David Naylor Student Commons)**

**Website:** <http://microbeto.ca/mid-2019/>

---

### Monday, June 3<sup>rd</sup>, 2019

#### **9:30 - 9:40 WELCOME ADDRESS**

##### **9:45 – 10:00: Avid Mohammadi**

Characterizing the impact of penile-vaginal sex on HIV-susceptible CD4<sup>+</sup> T cell subsets in the female genital tract

##### **10:05 - 10:20: Erin O. Y. Wong**

Developing defined microbiota to model inflammation in the mouse gut

##### **10:25 - 10:40: Nora Mellouk**

An ATG16L1-dependent pathway promotes plasma membrane repair and limits *Listeria monocytogenes* cell-to-cell spread

#### **10:45 - 11:15: COFFEE BREAK**

##### **11:20 - 11:35: Jean-Paul R. Soucy**

Joint modelling of resistance to six antimicrobials in urinary *Escherichia coli* isolates in Quebec, Canada

##### **11:40 – 11:55: Sarah Birstonas**

EHEC utilizes two-component systems to modulate expression of major flagellar subunit protein, FliC, in response to host intestinal cues

##### **12:00 - 12:15: Nathaniel Winsor**

NLRP6 regulates the colonic mucus layer during *Trichomonas* infection

#### **12:35 – 1:30: LUNCH**

##### **1:35 - 12:50: Samuel Salamun**

Epstein-Barr Virus Protein BMRF1 Modulates Cellular SUMO and DNA Damage Response Pathways by Binding the Cellular NuRD Complex

##### **1:55 - 2:10: Nicola Case**

Elucidating the mechanism of *Candida albicans* morphogenesis in response to phagocytosis by macrophages

##### **2:15 - 2:30: Sarah Kronheim**

A small molecule anti-phage defense mechanism in *Streptomyces*

#### **2.30 - 3:00: COFFEE BREAK**

##### **3:05 - 3:20: Alexandra Willis**

Understanding inherited immunity using a *C. elegans* model of microsporidia infection

##### **3:25 - 3:40: Genevieve Mailhot**

Differentiating between protective and pathogenic neutrophil responses during *Neisseria gonorrhoeae* infection

##### **3:45 – 4:00: Tiffany Fitzpatrick**

Successes of anti-RSV prophylaxis among infants in Ontario: results from a multi-decade, population-based controlled interrupted time series analysis using health administrative data

# Poster Presentations

85) Sequence Heterogeneity in Leishmania RNA Virus-1 (LRV-1) Detected in Strains of *Leishmania Viannia* spp.

Ruwandi Kariyawasam<sup>1</sup>, Rachel Lau<sup>2</sup>, Braulio M. Valencia<sup>3</sup>, Alejandro Llanos Cuentas<sup>3</sup>,  
Andrea K. Boggild<sup>1,2,4</sup>

<sup>1</sup>Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada <sup>2</sup>Public Health  
Ontario Laboratories, Toronto, ON, Canada <sup>3</sup>Instituto de Medicina Tropical

Alexander von Humboldt", Lima, Peru <sup>4</sup>Tropical Disease Unit, UHN-Toronto General Hospital,  
Toronto, ON, Canada Leishmania RNA Virus (LRV) is classified as a Group III dsRNA virus  
belonging to the family Totiviridae, containing a 5284 nucleotide sequence. Two main types of  
LRV are known to infect strains of Leishmania: LRV-1 and LRV-2. LRV-1 in the New World  
has 14 subtypes (LRV-1-1 – LRV-1-14) predominantly isolated from the Amazon basin. Since  
the detection of LRV-1 in a patient with cutaneous satellite lesions and lymphatic involvement  
after visiting Suriname, the notion that LRV-1 in the parasite might be causing more severe  
disease has been the focus of evaluation over the past few decades. We wanted to understand  
whether sequence heterogeneity within the LRV-1 virus could contribute to the severe phenotype  
observed in some patients infected by the *Leishmania Viannia* spp. Nucleic acid was extracted  
from clinical cultured cells for species identification and LRV-1 detection using quantitative  
real-time PCR (qPCR). Cultures positive by qPCR were confirmed by end-point PCR and Sanger  
Sequencing using primers targeting LRV-1-1 and LRV-1-4 subtypes primarily known to  
circulate in Latin America. Of 56 available clinical cultures, 18 were positive by qPCR. To date,  
3/18 (16.7%) LRV-1 positive clinical cultures have been confirmed by end-point PCR with  
sufficient sequence product. The following species were identified: 2/3 (67%) *L. V. braziliensis*  
and 1/3 (33%) *L. V. panamensis*. A phylogenetic molecular analysis was performed using the  
Maximum Likelihood method (BioEdit version 7.2.5) post ClustalW Multiple alignment using  
the three previously mentioned clinical cultures, ATCC© 50126 *L. V. guyanensis* and NCBI  
reference genomes: NC002063.1 and NC00306.1. An unrooted tree was produced 2 distinct  
clusters whereby the 2 LRV-1 positive *L. V. braziliensis* and 1 ATCC© 50126 *L. V. guyanensis*  
strains were branched from the same node (length = 0.08639,  $p < 0.01$ ) while the LRV-1 positive  
*L. V. panamensis*, NC00306.4 and NC002063.1 strains branched from an unrelated node (length  
= 1.23789,  $p < 0.01$ ). Further analysis of the remaining LRV-1 positive cultures will provide  
more insight into the divergence of LRV-1 between species as well as implications into the  
severity of disease in ATL.